Quest Diagnostics Adds Diabetic Retinopathy Screening Through its Patient Service Centers in Collaboration with IRIS

SECAUCUS, N.J., April 4, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration with IRIS (Intelligent Retinal Imaging Systems) to deliver diabetic retinal imaging services through designated Quest Diagnostics patient service centers across the United States to aid in screening patients for retinal assessment by a healthcare provider. The collaboration aims to increase convenience and improve screening rates for diabetic retinopathy, the leading cause of blindness in the United Statesi, for members of population health management programs sponsored by health plans.